The Future of Biological Evaluation: ISO 10993-1 Update
Uncover how the upcoming ISO 10993-1 revision is reshaping biocompatibility into a continuous, lifecycle-driven process to ensure medical device safety and regulatory compliance.
Read Full Blog
PFAS Compliance and Medical Device Innovation
Discover how PFAS regulations impact medical device manufacturing, exploring the balance between unique material properties and safety compliance.
Read Article
CXOToday Interview on PFAS Regulations
Explore how evolving PFAS regulations are driving innovation in the medical device industry, prompting a shift towards safer material alternatives without compromising device quality.
Read ArticleEnsuring Medical Device Safety and Reliability with Biocompatibility Evaluations
In the rapidly evolving medical device industry, biocompatibility has become a critical focus area. With increasing regulatory scrutiny and technological advancements, there is a shift towards more sophisticated and accurate methods for ensuring device safety, emphasizing the 3R principle of animal usage (Reuse, Reduce, and Recycle). Ensuring medical device biocompatibility presents challenges such as managing material changes, implementing robust risk management strategies, and conducting rigorous chemical profiling.
Evolving regulations demand continuous refinement of analytical methods and a deep understanding of materials and manufacturing processes. Tata Elxsi addresses these challenges with robust risk management, thorough chemical profiling, and the adoption of innovative in vitro and silico testing methods. We continuously refine our analytical methods and evaluate alternatives to existing materials and processes, ensuring the delivery of safe, reliable, and compliant medical devices.
Ensuring Excellence in Biocompatibility Compliance as per the new EU MDR Standards
Here’s How We Can Help
Stringent assessment by regulatory authorities
- Comprehensive medical device biocompatibility evaluations according to the latest ISO 10993 series & US FDA biocompatibility requirements.
- Expert interpretation of complex biocompatibility data to help make critical business decisions.
Adhering to chemicals & substances regulations for medical device raw materials & manufacturing processes
- Comprehensive chemical assessments to manage potential risks in device manufacturing.
- Toxicological risk assessment to supplement chemical analysis.
- Guidance on regulatory compliance with environmental, health & safety guidelines.
Preparing for the future of biocompatibility testing
- Theoretical methods for assessment & justification to avoid animal testing.
- Alternative testing methods & risk assessment strategies to inform product development decisions.
- Product portfolio filtering using worst-case assessments to funnel only "must-have" products for testing.
Medical Device Biocompatibility Service Offerings
Our biocompatibility services framework delivers end-to-end support for regulatory-compliant product safety evaluation. It spans strategy development, testing coordination, and regulatory submission, tailored to meet ISO 10993, EU MDR, and FDA requirements. The service includes gap assessments, biological risk analysis, lab coordination, report generation, and regulator-ready safety documentation. From new product development to legacy device remediation, the framework ensures product safety, accelerates compliance timelines, and provides expert support during global regulatory interactions.
Strategic Planning & Compliance Execution
The process begins with strategy development for NPI/NPD, legacy devices, M&A, and lifecycle management. It includes gap assessments against ISO 10993, ISO 18562, EU MDR, and FDA standards, as well as impact assessment and CAPA remediation. This flows into execution for end-to-end compliance, covering risk analysis, biological evaluation planning, benefit-risk analysis, additional safety testing, and toxicological risk assessments.
Lab Coordination & Testing Oversight
The lab co-ordination phase ensures rigorous control over testing activities. It includes testing design strategy, test protocol review and approval, sample selection, and study monitoring. Results are reviewed through detailed test report evaluations, helping ensure studies meet regulatory expectations and support overall product safety assessments effectively.
Reporting & Regulatory Submission
The reporting phase includes TRA (Toxicological Risk Assessment) report preparation, technical justification writing, and BER (Biological Rvaluation Reports) to conclude final device safety. Finally, assistance with regulatory submission ensures that biocompatibility evaluations are submission-ready and compliant, with expert support provided in responding to deficiencies or queries raised by global regulators.
Why Tata Elxsi
- Leveraging diverse domain expertise for end-to-end biocompatibility alignment with EU MDR & ISO 10993 standards.
- Streamlining product portfolios and minimizing animal testing by up to 90% with worst-case assessments and customized solutions.
- Ensuring swift risk mitigation and timely submissions to notified bodies, expediting the compliance process.
- Managing complex supply chains with dedicated supplier coordination and vendor management.
- Agile lab coordination to save 20–25% on testing costs, improve test slot availability and reduce waiting periods.
In Focus
Information Hub
-
How do TRA and BER support medical device biocompatibility?
Toxicological Risk Assessment (TRA) and Biological Evaluation Reports (BER) are critical tools for demonstrating medical device biocompatibility. TRA helps quantify chemical exposure risk, while BER systematically documents biological safety evidence aligned with ISO 10993 standards. Together, they support regulatory submissions by ensuring patient-contacting materials do not pose adverse effects, helping manufacturers meet global safety requirements, optimize testing strategies, and accelerate market access for innovative medical devices.
